Friday, 16 October 2026European Markets

TFF GROUP And BAINS MER MONACO Have A High Dividend Yield And Return On Equity In The Consumer Cyclical Sector.

Loading stream...

(vianews) - tff group (tff.pa) is among this list of stock assets with the highest dividend rate and return on equity on the consumer cyclical sector.

financial asset price forward dividend yield return on equity
tff group (tff.pa) €44.30 1.34% 12.23%
bains mer monaco (bain.pa) €103.00 1.15% 5.66%

several euronext companies pay out dividends to its shareholders. the dividend yield is a dividend to price ratio showing how much a company pays out in dividends each year.

1. tff group (tff.pa)

1.34% forward dividend yield and 12.23% return on equity

tff group, together with its subsidiaries, manufactures and distributes barrels and wood products for the aging of wines and alcohols in france, rest of europe, the united states, asia, and internationally. the company offers forestry and logging, stave milling, whisky and bourbon cooperages, cask making, wood and oenological products, and stainless-steel containers. it primarily serves wine, bourbon, and whisky markets. the company was formerly known as tonnellerie françois frères. tff group was founded in 1910 and is based in saint-romain-de-colbosc, france.

earnings per share

as for profitability, tff group has a trailing twelve months eps of €2.44.

pe ratio

tff group has a trailing twelve months price to earnings ratio of 18.16. meaning, the purchaser of the share is investing €18.16 for every euro of annual earnings.

return on equity

the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 12.23%.

volume

today's last reported volume for tff group is 328 which is 93.46% below its average volume of 5019.

volatility

tff group's last week, last month's, and last quarter's current intraday variation average was a negative 1.34%, a positive 0.09%, and a positive 1.46%.

tff group's highest amplitude of average volatility was 1.34% (last week), 1.06% (last month), and 1.46% (last quarter).

more news about tff group.

2. bains mer monaco (bain.pa)

1.15% forward dividend yield and 5.66% return on equity

société anonyme des bains de mer et du cercle des étrangers à monaco operates in the gaming, hotels, and rental sectors in monaco. the company operates casinos; hotels; restaurants; lounge bars and nightclubs; wellness and leisure facilities; shows and concert halls; shopping centers; and meetings and events centers. it is also involved in the slot machines, table games, and other activities; and rental of residential properties, boutiques, and offices. in addition, the company offers catering services. the company was incorporated in 1863 and is headquartered in monaco.

earnings per share

as for profitability, bains mer monaco has a trailing twelve months eps of €3.63.

pe ratio

bains mer monaco has a trailing twelve months price to earnings ratio of 28.37. meaning, the purchaser of the share is investing €28.37 for every euro of annual earnings.

return on equity

the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 5.66%.

volatility

bains mer monaco's last week, last month's, and last quarter's current intraday variation average was 0.16%, 0.05%, and 0.88%.

bains mer monaco's highest amplitude of average volatility was 0.80% (last week), 0.91% (last month), and 0.88% (last quarter).

more news about bains mer monaco.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,378 source documents archived
Query this data → isubstrate.com